Freedom of information requests

Biliary Tract and Non-Small Cell Lung Cancer Treatment

Questions

1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) withDurvalumab for the following indications?
2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) withNivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
3. How many unique total patients were treated last month (March 24) withDurvalumab for the following indications?
4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
    
   • Biliary Tract Cancer
   • Non-Small Cell Lung Cancer

Response

1. 

Type of Cancer	No. of Unique Patients
Biliary Tract Cancer	0
Non-Small Cell Lung Cancer	0

2. 

Following a search of our paper and electronic files and records, the information you have requested is not held. Therefore, there is no recorded information held to answer this under the Freedom of Information Act 2000.

3.

Type of Cancer	No. of Unique Patients
Biliary Tract Cancer	0
Non-Small Cell Lung Cancer	0

4.

Following a search of our paper and electronic files and records, the information you have requested is not held. Therefore, there is no recorded information held to answer this under the Freedom of Information Act 2000.